TMCnet News
Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational ResearchSOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the appointment of Grant Blouse, Ph.D., as vice president of translational research. “We are delighted that Dr. Grant Blouse will be joining Catalyst as vice president of translational research,” said Nassim Usman, chief executive officer of Catalyst. “Dr. Blouse brings over 20 years of experience in hematology research and development, including most recently supporting coagulation R&D programs at Novo Nordisk for six years. He will be supporting the development of our hemophilia programs and our research pipeline. We are confident in his ability to immediately contribute to our Factor IX CB 2679d/ISU304 and Factor VIIa marzeptacog alfa clinical programs.” Dr. Blouse was most recently principle scientist and project manager at Novo Nordisk A/S, Haemophilia Enzymology, where he led early and late stage hemophilia projects and drove the strategic evaluation of new therapeutic areas in the rare disease space. Prior to Novo Nordisk, Dr. Blouse was a senior scientist at Catalyst Biosciences where he helped to build Catalyst’s next-generation hemophilia franchise, including helping to identify Catalyst’s Factor VIIa candidate marzeptacog alfa (activated) and co-inventing its Factor IX candidate CB 2679d/ISU304. Dr. Blouse has held research and investigator positions at Aarhus University’s Department of Molecular Biology, Henry Ford Health System’s Division of Biochemical Research and Wayne State University School of Medicine’s Department of Pharmacology. He has authored more than 50 peer reviewed papers and abstracts and delivered moe than a dozen invited talks in the biochemistry and hematology spaces. Dr. Blouse earned his B.A. in anthropology from the University of Delaware, his M.Sc. in biochemistry from Clemson University and his Ph.D. in pharmacology from Wayne State University School of Medicine. About Catalyst Forward-Looking Statements Contacts Investors: Media: |